Acromegaly Market to Reach $4.93 Billion by 2029, Growing at a CAGR of 17.8%

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Acromegaly Industry By The Forecast Year 2029?

The acromegaly market has seen significant expansion in recent times. Its value is projected to rise from $2.15 billion in 2024 to $2.56 billion in 2025, achieving a compound annual growth rate (CAGR) of 19.3%. Historically, this market growth has been primarily due to the increasing incidence of acromegaly therapeutics, greater public awareness regarding acromegaly, various government initiatives, and the strong demand for effective treatments.

The acromegaly market is anticipated to undergo significant expansion over the next few years. It is projected to reach $4.93 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.8%. This growth within the forecast period can be attributed to increased investments in research and development for acromegaly treatments, a rising number of screening programs, escalating healthcare spending, and a growing demand for less invasive treatment options. Prominent trends expected during this period include new acromegaly treatments, the advancement of targeted therapies for acromegaly, a robust pipeline of drugs, enhancements in available treatment options, and sophisticated personalized medicine approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Which Industry Drivers Are Expected To Accelerate The Acromegaly Market From 2025 To 2029?

The expanding incidence of hormonal diseases, such as diabetes, is projected to fuel the future growth of the acromegaly market. Hormonal diseases, also termed endocrine disorders, are medical conditions stemming from dysfunctions within the endocrine system. Diabetes stands out as one of the most widespread and critical hormonal diseases. The excessive production of specific hormones, including growth hormone or cortisol, can lead to acromegaly and other endocrine conditions. Furthermore, owing to the effect of elevated growth hormone levels on insulin synthesis, approximately 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, revealed that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it saw a 21% rise, while the percentage achieving target HbA1c levels climbed to 37.9%, representing the highest value ever reported by the National Diabetes Audit (NDA). Consequently, the rising number of hormonal diseases is actively driving the expansion of the acromegaly market.

What Are The Segment Types Shaping The Acromegaly Market?

The acromegalymarket covered in this report is segmented –

1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis

3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations

4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments

5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly; Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess; Secondary Growth Hormone Excess

What Long-Term Trends Will Shape The Future Growth Of The Acromegaly Industry?

Major companies operating in the acromegaly market are actively pursuing the development of innovative products and solutions, such as generic lanreotide, to broaden treatment options and enhance patient outcomes. Generic lanreotide represents a non-branded formulation of the drug used for treating acromegaly and specific neuroendocrine tumors. It functions as a somatostatin analogue, effectively reducing growth hormone secretion and improving patient accessibility to beneficial treatment alternatives. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company specializing in generic drugs, introduced the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is prescribed for managing acromegaly and severe diarrhea associated with carcinoid syndrome. The introduction significantly boosts access to essential therapy for patients who require these treatments.

Who Are The Top Performing Companies In The Acromegaly Market In Recent Years?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Acromegaly Market?

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Acromegaly Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2025, By The Business Research Company

Generic Central Nervous System Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

Nerve Repair And Regenerative Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Central Nervous System Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795